A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

By Ajani Jaffer   Jiang Yixing   Faust Josephine   Chang Baochong   Ho Linus   Yao James   Rousey Steven   Dakhil Shaker   Cherny Richard   Craig Catherine   Bleyer Archie  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 353-357

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer

By Miller Kathy D.   Soule Sharon E.   Haney LaTrice G.   Guiney Patricia   Murry Darryl J.   Lenaz Luigi   Sun Show-Li   Sledge Jr George W.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 69-73

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

By Ernst D   Eisenhauer Elizabeth   Wainman Nancy   Davis Mary   Lohmann Reinhard   Baetz Tara   Belanger Karl   Smylie Michael  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 569-575

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study

By Martin-Richard M.   Gallego R.   Pericay C.   Foncillas J.   Queralt B.   Casado E.   Barriuso J.   Iranzo V.   Juez I.   Visa L.   Saigi E.   Barnadas A.   Garcia-Albeniz X.   Maurel J.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1573-1579

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

By Kato Ken  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1621-1627

Springer Publishing Company

Access to resources Recommend Favorite